These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study. Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM; AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848 [TBL] [Abstract][Full Text] [Related]
4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
5. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. Maggiolo F; Airoldi M; Callegaro A; Martinelli C; Dolara A; Bini T; Gregis G; Quinzan G; Ripamonti D; Ravasio V; Suter F AIDS; 2009 Apr; 23(7):799-807. PubMed ID: 19114869 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment. Sarmati L; Andreoni C; Nicastri E; Tommasi C; Buonomini A; D'Ettorre G; Corpolongo A; Dori L; Montano M; Volpi A; Narciso P; Vullo V; Andreoni M J Med Virol; 2009 Mar; 81(3):481-7. PubMed ID: 19152399 [TBL] [Abstract][Full Text] [Related]
8. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection. Boschi A; Tinelli C; Ortolani P; Arlotti M J Antimicrob Chemother; 2006 Mar; 57(3):520-6. PubMed ID: 16387747 [TBL] [Abstract][Full Text] [Related]
9. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447 [TBL] [Abstract][Full Text] [Related]
10. Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome. Voirin N; Routy JP; Smith D; Baratin D; Trépo C; Cotte L; Touraine JL; Livrozet JM; Cooper DA; Ritter J; André P; Vanhems P HIV Med; 2008 Jul; 9(6):440-4. PubMed ID: 18705761 [TBL] [Abstract][Full Text] [Related]
11. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients]. Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327 [TBL] [Abstract][Full Text] [Related]
12. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864 [TBL] [Abstract][Full Text] [Related]
13. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114 [TBL] [Abstract][Full Text] [Related]
15. Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1. Hasson H; Mantelli B; Biswas P; Malnati M; Gianotti N; Vecchi A; Nozza S; Cernuschi M; Boeri E; Clerici M; Lazzarin A; Beretta A J Med Virol; 2007 Nov; 79(11):1640-9. PubMed ID: 17854028 [TBL] [Abstract][Full Text] [Related]
16. Preference for CD4-guided versus continuous HARRT in Thailand. Ananworanich J; Pumpradit W; Apateerapong W; Siangphoe U; Saenawat S; Phanuphak P; Hirschel B AIDS Care; 2008 Mar; 20(3):327-30. PubMed ID: 18351480 [TBL] [Abstract][Full Text] [Related]